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Placental PHLDA2 expression is increased in
cases of fetal growth restriction following
reduced fetal movements
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Abstract
Background: Maternal perception of reduced fetal movements (RFM) is associated with increased risk of fetal
growth restriction (FGR) and stillbirth, mediated by placental insufficiency. The maternally expressed imprinted gene
PHLDA2 controls fetal growth, placental development and placental lactogen production in a mouse model. A
number of studies have also demonstrated abnormally elevated placental PHLDA2 expression in human growth
restricted pregnancies. This study examined whether PHLDA2 was aberrantly expressed in placentas of RFM
pregnancies resulting in delivery of an FGR infant and explored a possible relationship between PHLDA2 expression
and placental lactogen release from the human placenta.
Methods: Villous trophoblast samples were obtained from a cohort of women reporting RFM (N = 109) and
PHLDA2 gene expression analysed. hPL levels were assayed in the maternal serum (N = 74).
Results: Placental PHLDA2 expression was significantly 2.3 fold higher in RFM pregnancies resulting in delivery of an
infant with FGR (p < 0.01), with highest levels of PHLDA2 expression in the most severe cases. Placental PHLDA2
expression was associated with maternal serum hPL levels (r = −0.30, p = 0.008, n = 74) although this failed to reach
statistical significance in multiple linear regression analysis controlling for birth weight (p = 0.07).
Conclusions: These results further highlight a role for placental PHLDA2 in poor perinatal outcomes, specifically FGR
associated with RFM. Furthermore, this study suggests a potential relationship between placental PHLDA2
expression and hPL production by the placenta, an association that requires further investigation in a larger cohort.
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Background
Maternal perception of reduced fetal movements (RFM) is
associated with an increased risk of poor perinatal out-
comes such as fetal growth restriction (FGR), preterm
birth, fetal distress, and stillbirth [1–7]. Placental insuffi-
ciency, the reduced ability of the placenta to supply
nutrients and oxygen to the fetus, could explain the co-
occurrence of RFM and FGR [8]. Placental insufficiency is
thought to primarily result in asymmetric FGR with pro-
longed exposure resulting in RFM (as a mechanism for
conserving energy for vital functions) and, if this remains
undetected, stillbirth [8]. Indeed, altered placental struc-
ture and function has been reported in RFM pregnancies
[9–12]. For example, RFM placentas are smaller, lighter
and exhibit a specific reduction in the syncytiotrophoblast
layer of the placenta [9], which synthesises hormones such
as human placental lactogen (hPL) for release into the ma-
ternal circulation [13].
Imprinted genes are monoallelically expressed with ex-
pression depending on the parent of origin [14]. These
genes have well-established roles in controlling fetal growth
and placental development, and are regulated by epigenetic
marks that may respond to environmental stimuli [15–17].
A subset of imprinted genes also converge on the endocrine
lineages of the mouse placenta to regulate placental hor-
mone production [18]. The maternally expressed imprinted
gene PLECKSTRIN HOMOLOGY-LIKE DOMAIN FAMILY
A MEMBER 2 (PHLDA2) exemplifies all of these functions.
Importantly, abnormally elevated placental PHLDA2
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expression has been associated with FGR and/or low birth
weight in a number of studies (reviewed in [16]). Modelling
similar overexpression of Phlda2 in a mouse model results
in FGR [19, 20], inferring that the association observed in
human pregnancies is causal. Moreover, the growth restric-
tion which occurs in response to Phlda2 overexpression is
late onset and asymmetric, followed by rapid postnatal
catch up growth [20], which is typical of human pregnan-
cies complicated by placental insufficiency. The Phlda2
overexpression mouse model also exhibits stunted placental
growth with a specific reduction in a key endocrine lineage
and impaired placental lactogen production [19, 21], con-
sistent with the altered endocrine function observed in hu-
man RFM placentas [9, 12].
In this study we analysed PHLDA2 expression in a cohort
of women reporting RFM (N = 109). We hypothesised that
placental PHLDA2 expression is specifically increased in
RFM pregnancies complicated by FGR (N = 20). We also
analysed maternal serum hPL levels (N = 74) in the RFM
cohort to explore the potential link between PHLDA2 ex-
pression and placental lactogen in the human placenta.
Methods
Participant recruitment
Study participants included women delivering within
one week of presentation with maternal perception of
RFM (after 28 weeks gestation) [2, 9]. Written informed
consent was obtained from the participants and the
study was approved by Oldham and Greater Manchester
North Research Ethics Committees (REC no. 08/1011/83
and 11/NW/0664). Fetal growth restriction was defined
as customised birth weight centile <10th [2]. Participant
demographics are shown in Table 1.
Sample collection
Villous trophoblast samples were obtained within
30 min of delivery [9]. As intraplacental variation in
PHLDA2 expression has previously been demonstrated
[22], samples were consistently taken midway between
the cord insertion and distal edge. Maternal venous
serum samples were obtained on admission (N = 74) and
hPL levels measured by ELISA (Immunodiagnostic sys-
tems, Boldon, UK) as previously described [2].
Gene expression analysis
Total RNA was extracted from the placental tissue sam-
ples using GenElute Mammalian Total RNA Miniprep
Kit (Sigma-Aldrich, Dorset, UK). 5 μg of RNA was re-
verse transcribed using M-MuLV reverse transcriptase
(Promega, Southampton, UK) with random hexamers,
according to manufacturer’s instructions. Quantitative
RT-PCR was performed using Chromo 4 Four Colour
Table 1 Participant demographics of RFM participants (N = 109)
Mean (SD)/Range or Number (%) Mean (SD)/Range or Number (%)
Birth outcomes
Fetal sex Ethnicity
Male 56 (51 %) Caucasian 73 (67 %)
Female 53 (49 %) African/Afro-Caribbean 10 (9 %)
Gestational age (days) 278 (13)/211 – 295 Indian/Pakistani/Bangladeshi 21 (19 %)
Birth weight (g) 3306 (599)/850 - 4680 Other 5 (5 %)
Custom birth weight centile 40 (29)/0 - 100 Parity 1 (1.22)/0 – 7
Placental Weight (g) 587 (127)/353 – 854 Smoking during Pregnancy
Apgar Scores (1 min) 9 (1.66)/0 - 10 Yes 17 (16 %)
Apgar Scores (5 min) 10 (1.39)/0 – 10 No 92 (84 %)
Mode of Delivery Alcohol consumption
SVD 61 (56 %) None 107 (98 %)
ELCS 10 (9 %) 1-5 units/week 2 (2 %)
EMCS 14 (13 %) Obstetric complications
Instrumental 24 (22 %) None 84 (77 %)
Maternal characteristics Preeclampsia/PIH/Proteinuria 5 (5 %)
Age (years) 29 (5.81)/17 – 46 Repeat RFM 10 (9 %)
Maternal BMI 25.78 (5.26)/17 – 46 Oligohydramnios 1 (1 %)
Suspected growth restriction 3 (3 %)
Other 4 (4 %)
Mean (SD)/Range or Number (%)
RFM reduced fetal movements, BMI body mass index, PIH pregnancy induced hypertension
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Real Time Detector (MJ Research) in a 20 μl reaction
containing 5 μl of cDNA (diluted 1 in 50), 1X Buffer
2 mM MgCl2, 2 mM dNTPs, 0.65 Units Taq (Fermentas
(Thermo), Loughborough, UK), 1 μM of each primer
(Sigma-Aldrich, Dorset, UK) and 0.12X Sybr Green
(Invitrogen, Paisley, UK). All samples were run in tripli-
cate and duplicate plates were performed. Conditions for
amplification were: 1) 15 min at 94 °C, 2) 30 s at 94 °C,
3) 30 s at 60 °C, 4) 30 s at 72 °C and 5) 30 s 75 °C, with
steps 2–5 repeated for a total of 40 cycles. Melt Curve
was performed from 70 to 94 °C, reading every 0.5 °C
and holding for 2 s. Primer sequences were as follows:
YWHAZ forward: TTCTTGATCCCCAATGCTTC & re-
verse: AGTTAAGGGCCAGACCCAGT, PHLDA2 for-
ward: GAGCGCACGGGCAAGTA & reverse: CAGCG
GAAGTCGATCTCCTT [23] and L19 forward: CCAAC
TCCCGTCAGCAGATC & reverse: CAAGGTGTTTTT
CCGGCATC [24].
Statistical analysis
Gene expression data is presented as the ΔCT (target
gene expression relative to the housekeeping gene
YWHAZ) and as the fold change in expression, calcu-
lated using the 2 -ΔΔCT method [25]. The geometric
mean of two housekeeping genes, YWHAZ and L19, was
used to confirm results obtained using the single
housekeeping gene, YWHAZ, for a subset of samples.
Parametric statistical tests were used to analyse normally
distributed data. The effect of potential confounders
(infant birth weight, gender and gestational age) was
examined using multiple linear regression analysis. To
ease interpretation, ΔCT values have been inverted
[x(−1)] such that lower values represent decreasing
gene expression.
Results
Placental PHLDA2 expression was significantly 2.3 fold
higher in RFM pregnancies resulting in delivery of a
growth restricted compared with a normal birth weight
infant (Fig. 1a). Results remained statistically signifi-
cant when comparing normalisation to a single house-
keeping gene YWHAZ with the geometric mean of
YWHAZ and L19 expression in a subset of samples
(Additional file 1: Figure S1).
When participants were further classified according
to severity of growth restriction, PHLDA2 expression
was significantly 1.7 fold higher in cases with custom
birth weight centile <10th (p = 0.01, n = 12. v. 82) and
3.2 fold higher in cases with custom birth weight cen-
tile <3rd (p < 0.001, n = 8 v. 82). Placental PHLDA2 ex-
pression was also significantly inversely associated
with birth weight (r = −0.24, p = 0.01, n = 109), custom
Fig. 1 Placental PHLDA2 expression in RFM pregnancies. Placental PHLDA2 expression was significantly increased in RFM pregnancies resulting in
delivery of a growth restricted infant (a) Fetal growth restriction was defined as delivery of a term infant with a custom birth weight centile
<10th. Placental PHLDA2 was not significantly altered in RFM pregnancies where infants were born preterm (b) or admitted to NICU at delivery
(c) There was a significant inverse association between placental PHLDA2 expression and maternal serum hPL levels (d) RFM = reduced fetal
movements. Error bars represent SEM. ** P < 0.01
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birth weight centiles (r = −0.25, p = 0.01, n = 109) and,
in this study, also placental weight (r = −0.39, p = 0.03,
n = 31).
We subsequently analysed placental PHLDA2 expres-
sion in relation to preterm delivery and NICU admission
at birth, which are other common poor perinatal out-
comes associated with RFM. There was no significant cor-
relation between placental PHLDA2 expression and
gestational age (r = −1.41, p = 0.14, n = 109) and was no
significant difference in expression between preterm and
term deliveries (Fig. 1b). Placental PHLDA2 expression
was not significantly altered in infants admitted to NICU
at delivery (for perinatal asphyxia) (Fig. 1c) and there was
no significant correlation between placental PHLDA2
and other measures of infant wellbeing at delivery in-
cluding Apgar scores at 1 min (r = 0.01, p = 0.93, n =
106) and 5 min (r = −0.11, p = 0.27, n = 105) or with ar-
terial cord blood pH (r = − 0.7, p = 0.52, n = 76).
Imprinted genes have been demonstrated to regulate
the endocrine lineage of the mouse placenta, in particu-
lar expression of placental lactogens [18]. In this study
there was a significant inverse association between pla-
cental PHLDA2 expression and maternal serum hPL
levels (Fig. 1d) suggesting that PHLDA2 may regulate
the production of placental hormones in human preg-
nancies. In further multiple linear regression analysis
controlling for infant birth weight, offspring gender and
gestational age (F(4,69) = 5.34, p = 0.001, R2 = 0.24), the
association between placental PHLDA2 expression and
serum hPL levels failed to reach statistical significance
(p = 0.07), with only infant birth weight significantly as-
sociated with maternal serum hPL levels (p = 0.01). This
is perhaps not surprising since, in the mouse model, ele-
vated Phlda2 drives both growth restriction and reduced
expression of placental lactogens [19, 21]. Data from the
animal model supports a causal association between pla-
cental PHLDA2 expression and maternal serum hPL levels.
Discussion
A number of studies have demonstrated abnormally ele-
vated placental PHLDA2 in pregnancies complicated by
FGR (reviewed in [16]). The Phlda2 overexpression
mouse model exhibits FGR and impaired placental de-
velopment supporting a causal role for elevated PHLDA2
in human FGR [19, 20]. Uniquely, this study examined a
group of women reporting RFM, a group who are at
high risk of poor perinatal outcomes. Within this group,
there was a significant association between increased
placental PHLDA2 expression and FGR. Moreover, the
highest levels of PHLDA2 expression were present in the
most severely growth restricted cases which also had the
most severe placental phenotype [12]. Placental weight
was also significantly inversely associated with PHLDA2
expression, which has not previously been reported. This
is of clinical interest as RFM is thought to represent a
fetal adaptation to prolonged placental insufficiency
which, if undetected, may result in stillbirth [8]. While
all participants in the current study delivered live born in-
fants, increased expression of PHLDA2 has previously
been reported in cases of spontaneous miscarriage or fetal
death [26] and more specifically, in cases of fetal death at-
tributed to FGR [27]. These results further highlight a role
for placental PHLDA2 in poor perinatal outcomes.
Our second key finding in this study was the significant
association between elevated placental PHLDA2 expres-
sion and decreased maternal hPL serum levels. After con-
trolling for birth weight, this association failed to reach
statistical significance (p = 0.07) but this can be explained
if, as in the mouse [19, 21], elevated PHLDA2 drives both
growth restriction and reduced placental lactogen expres-
sion. hPL plays an important role in maternal glucose
management during pregnancy and in the control of fetal
growth [28]. This relationship between placental PHLDA2
expression and placental hPL production would therefore
be of considerable interest in understanding the mecha-
nisms driving poor growth in utero.
Conclusion
This study demonstrated significantly elevated PHLDA2 ex-
pression in placentas of RFM pregnancies resulting in deliv-
ery of a growth restricted infant and identified an
association between placental PHLDA2 expression and
serum hPL levels. It has previously been suggested that
PHLDA2 expression in the placenta could be used to post-
natally identify types of fetal growth restriction and thus in-
form subsequent infant care [16]. Identifying hormonal
biomarkers of abnormal placental PHLDA2 expression dur-
ing pregnancy could be further used as a prenatal diagnos-
tic tool to identify RFM pregnancies at risk of poor
perinatal outcomes. This is of particular importance in the
context of a recent UK report highlighting that more ap-
propriate, better informed management of RFM could have
prevented one third of the stillbirth cases examined [29].
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